These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25304634)

  • 1. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach.
    Langley I; Lin HH; Egwaga S; Doulla B; Ku CC; Murray M; Cohen T; Squire SB
    Lancet Glob Health; 2014 Oct; 2(10):e581-91. PubMed ID: 25304634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?
    Trébucq A; Enarson DA; Chiang CY; Van Deun A; Harries AD; Boillot F; Detjen A; Fujiwara PI; Graham SM; Monedero I; Rusen ID; Rieder HL
    Int J Tuberc Lung Dis; 2011 Dec; 15(12):1567-72. PubMed ID: 22005110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of the Xpert MTB/RIF assay for rapid diagnosis of suspected tuberculosis in an intermediate burden area.
    You JH; Lui G; Kam KM; Lee NL
    J Infect; 2015 Apr; 70(4):409-14. PubMed ID: 25573001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of giant African pouched rats for diagnosing tuberculosis: comparison with culture and Xpert
    Mulder C; Mgode GF; Ellis H; Valverde E; Beyene N; Cox C; Reid SE; Van't Hoog AH; Edwards TL
    Int J Tuberc Lung Dis; 2017 Nov; 21(11):1127-1133. PubMed ID: 29037292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries.
    Ardizzoni E; Fajardo E; Saranchuk P; Casenghi M; Page AL; Varaine F; Kosack CS; Hepple P
    PLoS One; 2015; 10(12):e0144656. PubMed ID: 26670929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.
    Shah M; Dowdy D; Joloba M; Ssengooba W; Manabe YC; Ellner J; Dorman SE
    AIDS; 2013 Nov; 27(18):2883-92. PubMed ID: 25119690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of Xpert MTB/RIF results for the detection of Mycobacterium tuberculosis in clinical samples].
    Ciftçi IH; Aslan MH; Aşık G
    Mikrobiyol Bul; 2011 Jan; 45(1):43-7. PubMed ID: 21341158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.
    Theron G; Zijenah L; Chanda D; Clowes P; Rachow A; Lesosky M; Bara W; Mungofa S; Pai M; Hoelscher M; Dowdy D; Pym A; Mwaba P; Mason P; Peter J; Dheda K;
    Lancet; 2014 Feb; 383(9915):424-35. PubMed ID: 24176144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of LED fluorescence microscopy in the diagnosis of pulmonary tuberculosis in Indian settings.
    Kelly V; Sagili KD; Satyanarayana S; Reza LW; Chadha SS; Wilson NC
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):696-701. PubMed ID: 25946362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling.
    Ejalu DL; Irioko A; Kirabo R; Mukose AD; Ekirapa E; Kagaayi J; Namutundu J
    BMJ Open; 2022 Aug; 12(8):e059823. PubMed ID: 35998960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic.
    O'Grady J; Bates M; Chilukutu L; Mzyece J; Cheelo B; Chilufya M; Mukonda L; Mumba M; Tembo J; Chomba M; Kapata N; Maeurer M; Rachow A; Clowes P; Hoelscher M; Mwaba P; Zumla A
    Clin Infect Dis; 2012 Nov; 55(9):1171-8. PubMed ID: 22806590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation.
    Pooran A; Theron G; Zijenah L; Chanda D; Clowes P; Mwenge L; Mutenherwa F; Lecesse P; Metcalfe J; Sohn H; Hoelscher M; Pym A; Peter J; Dowdy D; Dheda K
    Lancet Glob Health; 2019 Jun; 7(6):e798-e807. PubMed ID: 31097281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation.
    Vassall A; Siapka M; Foster N; Cunnama L; Ramma L; Fielding K; McCarthy K; Churchyard G; Grant A; Sinanovic E
    Lancet Glob Health; 2017 Jul; 5(7):e710-e719. PubMed ID: 28619229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting-A cost-effectiveness analysis.
    Fekadu G; Wang Y; You JHS
    PLoS One; 2023; 18(7):e0288605. PubMed ID: 37450476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study.
    Bates M; O'Grady J; Maeurer M; Tembo J; Chilukutu L; Chabala C; Kasonde R; Mulota P; Mzyece J; Chomba M; Mukonda L; Mumba M; Kapata N; Rachow A; Clowes P; Hoelscher M; Mwaba P; Zumla A
    Lancet Infect Dis; 2013 Jan; 13(1):36-42. PubMed ID: 23134697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.